Loading...
•
Jun 30, 2024
Zimmer Biomet Q2 2024 Earnings Report
Zimmer Biomet's Q2 2024 financial results were announced, demonstrating a strong performance driven by customer demand and international business strength.
Key Takeaways
Zimmer Biomet reported a strong Q2, exceeding expectations for both revenue and earnings. Net sales increased by 3.9% to $1.942 billion, and adjusted diluted earnings per share were $2.01. The company has updated its 2024 reported revenue guidance due to currency expectations and reaffirmed its constant currency revenue growth and adjusted EPS guidance.
Second quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency basis.
Second quarter diluted earnings per share were $1.18; adjusted diluted earnings per share were $2.01.
The Company updates 2024 reported revenue guidance due to currency expectations and reaffirms 2024 constant currency revenue growth and adjusted earnings per share financial guidance.
Company delivered a strong Q2 – beating expectations on both the top and bottom line, driven by customer demand and the strength and breadth of its international business
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Zimmer Biomet Revenue by Geographic Location
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comTech/Data/Surgical Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company is updating its full-year 2024 financial guidance to modify the expected foreign currency exchange impact and is reaffirming constant currency revenue growth as well as adjusted EPS guidance.
Positive Outlook
- Reaffirming constant currency revenue growth
- Adjusted Diluted EPS between $8.00 - $8.15
Challenges Ahead
- 2024 Reported Revenue Change 4.0% - 5.0%
- Foreign Currency Exchange Impact (1.0)%
Revenue & Expenses
Visualization of income flow from segment revenue to net income